KR20210135518A - 항-trem2 항체 및 이의 사용 방법 - Google Patents

항-trem2 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20210135518A
KR20210135518A KR1020217028927A KR20217028927A KR20210135518A KR 20210135518 A KR20210135518 A KR 20210135518A KR 1020217028927 A KR1020217028927 A KR 1020217028927A KR 20217028927 A KR20217028927 A KR 20217028927A KR 20210135518 A KR20210135518 A KR 20210135518A
Authority
KR
South Korea
Prior art keywords
seq
sequence
cdr
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217028927A
Other languages
English (en)
Korean (ko)
Inventor
마크 에스. 데니스
셰리에 던칸
캐슬린 리사인고
캐스린 엠. 몬로에
조슈아 아이. 박
레이첼 프로록
주 시
안키타 스리바스타바
벳티나 반 렌게리치
릴리 왈시
Original Assignee
데날리 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데날리 테라퓨틱스 인크. filed Critical 데날리 테라퓨틱스 인크.
Publication of KR20210135518A publication Critical patent/KR20210135518A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217028927A 2019-02-20 2020-02-20 항-trem2 항체 및 이의 사용 방법 Pending KR20210135518A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808141P 2019-02-20 2019-02-20
US62/808,141 2019-02-20
PCT/US2020/019093 WO2020172450A1 (en) 2019-02-20 2020-02-20 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20210135518A true KR20210135518A (ko) 2021-11-15

Family

ID=69844940

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028927A Pending KR20210135518A (ko) 2019-02-20 2020-02-20 항-trem2 항체 및 이의 사용 방법

Country Status (21)

Country Link
US (2) US20220073609A1 (enExample)
EP (1) EP3927743A1 (enExample)
JP (2) JP7543290B2 (enExample)
KR (1) KR20210135518A (enExample)
CN (1) CN113614110B (enExample)
AR (1) AR118144A1 (enExample)
AU (1) AU2020226754A1 (enExample)
BR (1) BR112021015656A2 (enExample)
CA (1) CA3130086A1 (enExample)
CL (1) CL2021002206A1 (enExample)
CO (1) CO2021012230A2 (enExample)
EA (1) EA202192294A1 (enExample)
EC (1) ECSP21069105A (enExample)
IL (1) IL285651A (enExample)
MA (1) MA55025A (enExample)
MX (1) MX2021009722A (enExample)
PE (1) PE20211979A1 (enExample)
PH (1) PH12021552002A1 (enExample)
SG (1) SG11202108734VA (enExample)
TW (1) TWI879756B (enExample)
WO (2) WO2020172457A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3902836A4 (en) * 2018-12-18 2022-08-31 Boehringer Ingelheim IO Canada Inc. FLT3 AGONISTIC ANTIBODIES AND THEIR USES
PE20211979A1 (es) 2019-02-20 2021-10-05 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
CN118765204A (zh) 2022-02-23 2024-10-11 艾利妥 抗trem2抗体的使用方法
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2024160736A1 (en) 2023-01-30 2024-08-08 Isar Bioscience Gmbh Human anti-trem2 antibody for treating neurodegenerative disorders
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025106361A1 (en) * 2023-11-15 2025-05-22 Merck Sharp & Dohme Llc Human nectin-4 binders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2746470A1 (en) 2009-01-06 2010-07-15 Raymond-David Pridmore Processing of macronutrients
EP2810652A3 (en) 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
JPWO2012176779A1 (ja) * 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
EP3041865A2 (en) 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR102506663B1 (ko) 2014-09-28 2023-03-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
WO2017062672A2 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017300040A1 (en) 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
EP3559043A4 (en) 2016-12-23 2020-08-05 Bluefin Biomedicine, Inc. ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
PL3583120T3 (pl) 2017-02-17 2023-01-09 Denali Therapeutics Inc. Konstruowane polipeptydy wiążące receptory transferyny
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
AU2018307877A1 (en) 2017-07-27 2020-01-02 Novartis Ag Sheddase resistant TREM2 variants
CA3061755A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof
PT3665192T (pt) 2017-08-10 2023-09-25 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
CA3075285A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
AU2019207735A1 (en) 2018-01-10 2020-07-23 Denali Therapeutics Inc. Transferrin receptor-binding polypeptides and uses thereof
US20210284702A1 (en) 2018-06-18 2021-09-16 Denali Therapeutics Inc. Fusion proteins comprising progranulin
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
CN112839955A (zh) 2018-08-16 2021-05-25 戴纳立制药公司 经工程改造双特异性蛋白
SG11202101436SA (en) 2018-08-22 2021-03-30 Denali Therapeutics Inc Anti-her2 polypeptides and methods of use thereof
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3121927A1 (en) 2018-12-10 2020-06-18 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
KR20210104079A (ko) 2018-12-11 2021-08-24 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem2 항체를 사용하는 방법
PE20211979A1 (es) 2019-02-20 2021-10-05 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
BR112021019520A2 (pt) 2019-04-03 2021-12-07 Denali Therapeutics Inc Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica
CN114981297A (zh) 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
AR121384A1 (es) 2020-02-19 2022-06-01 Denali Therapeutics Inc Proteínas biespecíficas anti-her2 diseñadas por ingeniería genética
MA71661A (fr) 2020-10-14 2025-05-30 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Also Published As

Publication number Publication date
CN113614110B (zh) 2025-03-25
TWI879756B (zh) 2025-04-11
JP7543290B2 (ja) 2024-09-02
CN113614110A (zh) 2021-11-05
EP3927743A1 (en) 2021-12-29
ECSP21069105A (es) 2021-11-18
JP2022520868A (ja) 2022-04-01
PH12021552002A1 (en) 2022-09-19
US12240902B2 (en) 2025-03-04
WO2020172457A1 (en) 2020-08-27
JP2024164116A (ja) 2024-11-26
EA202192294A1 (ru) 2021-12-24
TW202045543A (zh) 2020-12-16
PE20211979A1 (es) 2021-10-05
US20220073609A1 (en) 2022-03-10
SG11202108734VA (en) 2021-09-29
US20220119522A1 (en) 2022-04-21
MA55025A (fr) 2021-12-29
BR112021015656A2 (pt) 2021-10-05
CL2021002206A1 (es) 2022-04-22
MX2021009722A (es) 2021-09-14
WO2020172450A1 (en) 2020-08-27
IL285651A (en) 2021-09-30
CO2021012230A2 (es) 2021-09-30
AR118144A1 (es) 2021-09-22
AU2020226754A1 (en) 2021-09-16
CA3130086A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
US12240902B2 (en) Anti-TREM2 antibodies and methods of use thereof
US11124567B2 (en) Anti-TREM2 antibodies and methods of use thereof
JP7403441B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
TWI890727B (zh) 抗trem2 抗體及其使用方法
KR20240133705A (ko) 항-pilra 항체, 이의 용도, 및 관련 방법 및 시약
HK40063035A (en) Anti-trem2 antibodies and methods of use thereof
EA049305B1 (ru) Антитела к trem2 и способы их применения
HK40082564A (en) Anti-trem2 antibodies and methods of use thereof
US20250215077A1 (en) Monovalent anti-trem2 binding molecules and methods of use thereof
TW202515915A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902